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Much of the data behind these recommendations come from
Africa itself: Cote d'Ivoire, Uganda, Malawi, Zambia and South
Africa6-8,11-12 (and see Fig. 1 in Anglaret et al.22). How ought
health workers and planners to interpret these suggestions for
their region? 
CTX USE AND THE DEVELOPMENT OF
ANTIMICROBIAL RESISTANCE 
RESISTANCE TO REGIONAL BACTERIAL PATHOGENS 
AND MALARIA
The sulfonamide antimicrobials were discovered in 1932. A 
sulfonamide-trimethoprim combination was first registered in
1968.13 Sadly the general efficacy of CTX has been curtailed by
the rapid emergence of drug resistance. Among the enteric
bacteriaceae and the pneumococci, resistance to CTX is a
global phenomenon.14-16 Indeed, the level of CTX resistance in
many parts of central and southern Africa is high.11,14,17,18
Resistance is not confined to the bacterial kingdom. Point
mutations in the dihydrofolate reductase (dhfr) and
dihydropteroate synthetase (dhps) genes of Plasmodium
falciparum have rendered the malarial parasite resistant to
sulfadoxine-pyrimethamine (Fansidar), a sulfonamide anti-
malarial used widely throughout Africa.19,20
Sulfonamides prevent the conversion of para-aminobenzoic
acid to dihydrofolate via the inhibition of dihydropteroate
synthetase, DHPS. Trimethoprim blocks the subsequent
formation of tetrahydrofolate through blocking dihydrofolate
reductase (dhfr). All organisms require folate for their
metabolic needs. Mutations in and altered function of these
genes form the basis of much of the resistance to these drugs.
It has been noted that strains of Escherichia coli isolated in the
developing world are more often resistant to CTX than are
strains in developed regions. Climate, poverty, poor hygiene, a
weak health infrastructure, and the indiscriminate use and
abuse of antimicrobials have contributed to this.13 With regard
to sub-Saharan Africa, these factors are unlikely to change
soon. Drug resistance is transferable between microbial
kingdoms. The use of Fansidar in Malawi has been linked to the
local increase of CTX resistance in Streptococcus
pneumoniae.21
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The HIV/AIDS epidemic affects large numbers of people in sub-Saharan Africa. Most are unaware of their HIV status. Despite
two decades of scientific advance, the education of communities and the provision of antiretroviral medication to some, many
still succumb to the virus. Can this situation be changed? Antiretroviral (ARV) drugs have been shown to be effective in both
poor and rich communities.1,2 But for the majority, these agents remain unaffordable and difficult to access. After 2 years, the
public-sector ARV rollout programme in South Africa remains under-subscribed and under-utilised.3 Diets, vitamins,
micronutrients and herbal concoctions have been advocated.4 But none has provided the survival benefit, freedom from
opportunistic disease, and completeness of recovery, of antiretroviral therapy.5
In recent years, research in developing countries has suggested that the daily use of the sulfonamide combination antibiotic,
co-trimoxazole (CTX, trimethoprim-sulfamethoxazole, TMP/SMX), enhances the survival of infected adults and children.6-8 Co-
trimoxazole (CTX) use in patients with advanced HIV infection became widespread in the 1980s when efficacy against
Pneumocystis jiroveci pneumonia (PJP) was demonstrated. In this context, prophylactic CTX was commenced at CD4 levels of
200 cells/µl or less or following an AIDS-defining condition including PJP itself, prolonged and unexplained fever and weight
loss. It was discontinued once the CD4 count rose to and remained above 200 cells/µl for at least 6 months.9
But the landscape for prophylactic CTX use in Africa appears to be changing. Recent World Health Organization (WHO)
Guidelines have recommended expanding CTX use to all HIV-infected persons – where CD4 levels are unknown – with
symptomatic WHO stage 2, 3 or 4 disease and where CD4 counts are available, to all with counts below 350 cells/µl. All HIV-
infected persons with TB - pulmonary and non-pulmonary – are to be placed on CTX prophylaxis irrespective of their CD4 cell
count. A ‘universal option’ of ‘CTX to all’ is offered to those who live in regions of high HIV prevalence and inadequate health
care support.10 When is CTX prophylaxis stopped? ‘The general view is to continue CTX prophylaxis in adults – in resource-poor
settings – indefinitely.’10
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RESISTANCE TO P. JIROVECI
Despite inconsistent reporting, P. jiroveci is an important
African pathogen.24-26 Sulfonamide use has been followed by
dhps gene mutations in this organism. The gradual
accumulation of more and more resistant genes is likely to
lead to the high-grade sulfonamide resistance that has
become ‘usual’ in other microbes.27-32
Despite the high level of background bacterial resistance, the
use of CTX in HIV-infected Africans appears to confer survival
benefit against regional pathogens, not just at traditional CD4
levels below 200 cells/µl, where it would be expected to
prevent P. jiroveci pneumonia (PJP), but at levels in excess of
500 cells/µl.22,23 What then is CTX doing that is benefiting the
HIV infected? And were CTX to be used more widely in Africa,
what will this mean for further resistance to, and the use of,
this antimicrobial in the future? 
THE CLINICAL STUDIES
THE COTE D'IVOIRE STUDIES6,7
Two randomised placebo-controlled clinical trials evaluated
the role of CTX in subjects who either had a WHO stage 2 and
3 HIV diagnosis or presented with smear-positive pulmonary
tuberculosis (TB).6,7 The studies were performed by two groups
of investigators based in Abidjan, Cote d'Ivoire. Enrolment ran
from 1995/6 to 1998 with a median follow-up of
approximately 10 - 12 months. Patients were not provided
with ARV therapy. Primary end-points included the occurrence
of severe events, particularly death or hospital admission.
Secondary outcomes measured morbidity. Both studies were
discontinued prematurely in the light of significant benefit in
the CTX arms. Few adverse events were recorded in those
subjects receiving CTX. In the TB study, benefit was shown to
be greater in those whose CD4 level was below 350 but above
100 cells/µl. Anglaret et al.6 noted benefit across all CD4 strata:
below 200, between 200 and 499, and above 500 cells/µl.
Fewer episodes of pneumonia, isosporiasis, malaria and ‘acute
unexplained fever’ were reported. Subjects enrolled in the TB
study and taking CTX experienced fewer enteric and
bacteraemic infections. Importantly, the authors note that at
that time, many pathogens (including the pneumococci and
salmonellae) in the Abidjan area were still sensitive to CTX. 
In a subsequent letter to AIDS22 these researchers point out
that an Ivoirean consensus statement now recommends the
prophylactic use of CTX in all HIV-infected persons with a
WHO clinical stage 2, 3 or 4 diagnosis or who have CD4 cell
counts below 500 cells/µl. This view is endorsed by ‘the Global
AIDS Policy Model Investigators’, who in addition conclude
that prophylactic CTX is cost-effective in a developing world
scenario when started at or after WHO stage 2, i.e. at an early
stage of HIV infection.33
THE UGANDAN DATA12,23,34,35
Since 2001, Mermin and co-workers have been researching a
stable population of rural HIV-infected Ugandans. Subjects
were provided with ‘safe’ drinking water and CTX. In
subsequent follow-up studies ARVs were added, and later still,
mosquito-repellant impregnated bed nets. Overall mortality
and morbidity rates were examined in addition to rates of
occurrence of malaria, diarrhoea illnesses, the numbers of
clinic visits and hospital admissions. Participants provided
their own ‘internal’ controls: subjects were monitored for 5
months before commencing CTX therapy. 
Of bacterial isolates from study subjects 76% were found to be
resistant to CTX. Nonetheless, the use of CTX was associated
with a reduction in the number of episodes of diarrhoea and
fewer deaths. Daily CTX use was associated with a 72%
decrease in the rate of malaria among study subjects. Parasite
levels were lower. Although the death rate among the HIV-
infected was 28 times higher than that of uninfected
Ugandans, the use of CTX conferred a 46% reduction in death
in the former. Improved survival on CTX was significant only
for those whose CD4 levels were below 200 cells/µl or who had
a WHO stage 3 or 4 entry-level diagnosis. However, in a further
letter to AIDS 23 the authors note that in a sub-analysis of their
patients with CD4 levels in excess of 500 cells/µl, the annual
rate of decline of cells was less than that for the period prior
to the start of CTX prophylaxis. They argue for considering
commencing CTX prophylaxis at levels above 500 cells/µl.
In a related study the prophylactic use of CTX in HIV-positive
household members – usually parents – gave some degree of
protection to their uninfected children. Mortality was reduced
and there were fewer episodes of malaria or diarrhoea in these
children.34 Before and after CTX-resistance patterns of stool
pathogens appeared to remain unchanged and the benefit was
attributed to the improved survival of the index case (adult)
within the family. 
The researchers took their work further with an assessment of
the potential benefit of ARV therapy and mosquito-repellant
impregnated bed nets in subjects already taking prophylactic
CTX. Cumulative benefit was demonstrated with both
interventions: fewer episodes of malaria. Benefit for other
morbidities such as pneumonia, diarrhoea and bacteraemia
was not measured.35 These later sequential studies lacked
contemporaneous control groups and were observational in
design. The median duration of actual follow-up while on ART
and CTX was short, a mere 126 days. These studies took place
in a rural setting in Uganda. 
Similar results have been achieved in two peri-urban clinics in
Uganda: reduced mortality and fewer episodes of malaria.36
The latter study was non-randomised, used historical controls
and took place between August 1999 and March 2002. The
primary benefit seems to have been in malaria control,
whereas the incidence of diarrhoea with fever, herpes zoster
and oral thrush actually increased on CTX. Worryingly, subjects
on CTX had a greater decline in their CD4 cell counts while on
CTX. Likewise total white cell counts and mean neutrophil
counts were significantly reduced during this period. The fall
in CD4 cells and blood counts while on CTX is not discussed in
detail.
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The Ugandan studies support those from the Ivory Coast and
indicate that the role of CTX prophylaxis extends beyond just
the prevention of PJP in subjects whose CD4 counts are below
200 cells/µl. Much of this benefit reflects improved malarial
control. These clinical trials are not all alike: some have been
randomised and placebo-controlled while others have been
less tightly structured. The context – urban and rural
populations, differing target of primary pathogens and
differing resistance patterns – has not been identical. But
nonetheless the work has reflected the situation on the
ground and has been extremely valuable. The preventive value
of CTX appears to vary with regard to respiratory and enteric
infections. Its role against malaria is very convincing. 
ZAMBIA11
Researchers based in Lusaka, Zambia, have evaluated CTX
prophylaxis in HIV-infected children. Bacterial pathogens in
this region are mostly resistant to CTX. The study was double-
blind, randomised and placebo-controlled. It started in 2001
but ended prematurely in 2003 when data confirmed benefit
to those children on CTX. The median follow-up was 18.9
months. A small but equal number of children (4 - 5%) in both
groups were able to afford ARV therapy (ART). Fewer children
in the CTX arm died, and there were fewer hospital admissions
in this group. Mortality benefit was independent of age or CD4
category. Pneumonia was strongly associated with mortality
and was less frequent in the CTX arm. Somewhat surprisingly,
P. jiroveci was isolated in only 1 child. An earlier autopsy study
based in Lusaka revealed a high prevalence of PJP in this
community, 27.5% of children dying with lung disease.37
South African and Malawian researchers have confirmed a
high prevalence of PJP in this part of the subcontinent.24,25,38
Pneumocystis infections are notoriously difficult to nail. The
possibility remains that some benefit from CTX may have been
accounted for by occult Pneumocystis infections. Malaria was
not a significant pathogen in this group. Survival benefit
appears to be related to the reduction in respiratory disease. 
Chintu et al.11 recommend that ‘all children with clinical
features of HIV-infection should receive cotrimoxazole
prophylaxis irrespective of age and CD4 count’, ‘irrespective of
levels of background resistance to the drug’. In a region with
cost constraints and where only 5% of children are accessing
ART it would seem ill advised to contradict this opinion.
An adult CTX prophylaxis study, the LUCOT trial, has been
submitted for publication. The subjects are Zambians with
newly treated or previously treated pulmonary tuberculosis.
Results demonstrate a 45% reduction in mortality in the CTX
arm. The findings are discussed in the WHO Guidelines paper.10
A further Zambian study noted birth outcomes in pregnant
women given CTX prophylaxis. Results indicated reduced
chorioamnionitis, prematurity, and neonatal mortality in
children born to mothers on the CTX arm. The women had CD4
counts below 200 cells/µl.39
SOUTH AFRICA8
Grimwade et al.8 looked at the effectiveness of CTX on the
mortality of adults with TB in the Hlabisa district of rural
KwaZulu-Natal. The study utilised previously diagnosed TB
patients (1998 - 2000) from the community as historical
controls. HIV seroprevalence in the area – via anonymous
testing – had increased from 36% (1993) to 78% in 2001/2.
Despite counselling, only 5% of the 1 173 subjects recruited
for the study from 2001/2 agreed to be tested for HIV status;
80% tested positive. The researchers found a significant
reduction in death at 6 months in those given CTX. Despite
continuing with the trial, there was no change in mortality
after this period. Adherence to daily CTX had in fact dropped
to 43% by 6 months. Malaria was infrequently diagnosed and
was felt to be an unlikely reason for CTX-related benefit. The
authors admit that there were significant differences in ‘type
of TB’ between the historical cohort and the study subjects. In
addition no CD4 levels are given, nor was the degree of
immunological suppression of the subjects reflected in any
other data provided by the authors. Without this, it is difficult
to exclude benefit from Pneumocystis prevention as a
contributing factor.
GENERAL REMARKS
Patients with a history of severe reactions to CTX or other
sulfonamides and children with glucose-6-phosphate
dehydrogenase (G6PD) deficiency ought not to receive CTX
prophylaxis. Dapsone 2 mg/kg once daily orally (100 mg daily
in adults) is an alternative. Inhaled pentamidine for P. jiroveci
prophylaxis is expensive and generally unavailable in resource-
constrained areas. Neither dapsone nor inhaled pentamidine
possess the breadth of antimicrobial efficacy of CTX.
The continued requirement for CTX prophylaxis in patients
who are receiving highly active antiretroviral therapy (HAART)
is probably limited to those in whom reconstitution of the
immune system is adequate or who experience treatment
failure and subsequent regression of CD4 levels. In adults on
ART, CTX is stopped after a CD4 count above 200 cells/µl has
been achieved and maintained for at least 6 months after
starting HAART.40 This may take some time. The Development
of Antiretroviral Therapy for Africa (DART) Study examined the
CD4 cell response following the start of HAART in Ugandans.
Where subjects initiated ART with CD4 levels above 100 but
below 200 cells/µl it took a median of 24 weeks to return levels
to above 200. If the initial CD4 level was below 50, the median
time to achieve a level above 200 was 72 weeks10 (as quoted,
reference not given). Even on HAART, some patients fail to
achieve a level above 200 cells/µl, particularly where initial
CD4 levels were extremely low; prudence recommends
continuing CTX prophylaxis in such patients.41
INFANTS AND CHILDREN
In children aged under 1 year, CTX prophylaxis is provided
from 4 - 6 weeks of life and throughout this period,
irrespective of CD4 percentage or the use of HAART.
Opportunistic infections are common and life-threatening at
this age. There are no available data on the value of both
CURRENT WHO RECOMMENDATIONS AND USE OF
CTX IN HIV-INFECTED PERSONS IN 
RESOURCE-POOR REGIONS10
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HAART and CTX use in children in resource-poor areas.
European and USA guidelines discourage the continuous use
of both CTX and HAART in children provided immune
reconstitution has taken place9,42,43 (Table I).
ADOLESCENTS AND ADULTS
Should the initiation of CTX preventive therapy be restricted to
patients with CD4 counts below 200 cells/µl or AIDS-defining
diagnoses? Clearly the data that emerge from the studies
discussed in this paper suggest not. Mortality and morbidity
benefit occurs in those with CD4 counts above 200 cells/µl,
possibly even above 500, and/or with early WHO stage 2 and
3 disease.6,12,23 What is the upper level at which further benefit
cannot be demonstrated? Does CTX preventive therapy need to
be continued despite successful immune reconstitution on
HAART?
Most of the African data reflect a rather specific context:
poverty, little or no access to HAART, endemic malaria and/or
invasive enteric and respiratory infections. Can these results
be applied uniformly to the cities and rural districts of
southern Africa? 
Poverty exists in these cities, as do other determinants of poor
health outcomes: informal settlements, overcrowding,
contaminated and insecure water supplies, failing health and
hygiene structures, uneducated, displaced and disempowered
people. HIV/AIDS is defining the context of life lived in modern
Africa. In these ways the cities and rural regions of southern
Africa are not too different from the social environment
described in the above studies on CTX. However, there are
differences too. Malaria is less prevalent in the south of the
continent than in central and west Africa. Other organisms
that may respond to CTX therapy have variable regional
expression in Africa or variable resistance patterns to CTX –
S. pneumoniae, isosporiasis, non-typhoidal salmonellae,
toxoplasmosis and possibly even common enteric pathogens
such as E. coli. The local prevalence of these conditions may
influence the regional effectiveness of CTX prophylaxis.26
The rollout of ARVs in South Africa, Botswana and Namibia is
generally more widespread than in countries to the north and
the influence of immune reconstitution with ARV treatment is
likely to significantly diminish the need for CTX prophylaxis in
patients on HAART (Table II). 
These new WHO Guidelines suggest that where CD4 counts
are available, CTX should be given to all with a CD4 count
below 350 cells/µl, particularly in resource-poor settings
where malaria and invasive bacterial infections are common.
Similarly it is suggested that all patients with any form of TB
should start CTX prophylaxis irrespective of their CD4 cell
count. Long-term adherence to CTX is emphasised and may
well be difficult to implement widely, particularly where a
‘universal CTX-for-all-and-taken-indefinitely’’ approach is
followed. Women who require CTX prophylaxis and who fall
pregnant are urged to remain on CTX. The CTX is continued
even while breastfeeding.
Discontinuation of CTX is suggested in the context of immune
recovery or toxicity. However, in the absence of CD4 count
monitoring ‘no consensus was reached’ regarding stopping
CTX therapy. Discontinuation is suggested after a year on CTX
provided the patient is on HAART, has had no symptomatic
WHO stage 2, 3 or 4 events and has displayed reliable
adherence. CTX is to be restarted when the CD4 count again
Situation
HIV-exposed Confirmed HIV infection in infants and children
infants and 
children < 1 year 1 - 4 years > 5 years 
CTX prophylaxis CTX prophylaxis WHO stages Follow adult 
is universally is indicated 2, 3 and 4 recommen-
indicated, regardless of regardless of dations
starting at CD4% or CD4% 
4 - 6 weeks clinical status OR
after birth and of child any WHO 
continuing stage with a 
until cessation CD4 < 25%






Universal option: Prophylaxis for all infants and children born to
confirmed or suspected HIV-infected mothers. This strategy may be
considered in settings with high prevalence of HIV, high infant
mortality due to infectious disease, and limited health infrastructure.
[C-IV]
Note that the grading of recommendations as indicated in this WHO Table is
based upon the following: 
Strength of recommendation: 
A. Highly recommended. Should be followed.
B. Consider: Applicable in most situations.
C. Optional.
Level of evidence to support the recommendation:
I. At least one randomised controlled trial with clinical endpoints or several
relevant high-quality scientific studies.
II. At least one randomised controlled trial with surrogate markers, at least one
high-quality study or several adequate studies.
III. Observational cohort data, one or more case-controlled or analytical studies
adequately conducted.
IV. Expert opinion based on evaluation of other evidence.
TABLE I. WHO RECOMMENDATIONS WITH REGARD TO THE
INITIATION OF CTX PROPHYLAXIS IN INFANTS AND
CHILDREN10
Based on WHO clinical staging Based on WHO clinical staging 
criteria alone where the CD4 and CD4 cell count criteria
count is not available
WHO stage 3 or 4 [A-I] CD4 below 350 cells/µl 
[A-III] OR WHO stage 3
WHO stage 2 [A-III] or 4 and any CD4 level [A-I]
Universal option: Countries may choose to adopt a Universal CTX
for all HIV-infected persons irrespective of CD4 or clinical stage.
This strategy may be considered in settings with a high prevalence
of HIV and limited health infrastructure [C-III]
For grading of recommendations see Table I.
TABLE II. WHO RECOMMENDATIONS WITH REGARD TO THE
INITIATION OF CTX PROPHYLAXIS IN ADOLESCENTS AND
ADULTS IN RESOURCE-POOR REGIONS10
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falls below the starting value and/or when WHO stage 2, 3 or
4 events occur.10 In an attempt to avoid confusion as to the
cause of hepatic and skin toxicities, it is recommended that
CTX prophylaxis be started 2 weeks before commencing
HAART where the latter is available. Should the patient
develop breakthrough invasive infections, antibiotics other
than CTX are advised. This would also apply to the active
management of malaria, where a patient currently on CTX
would not be expected to derive benefit from sulfadoxine-
pyramethamine (Fansidar). Alternative antimalarials must be
used. 
CONCLUDING REMARKS
The current WHO recommendations for the use of CTX in
resource-poor regions focuses on communities where invasive
infections are frequent and are accompanied by significant
morbidity and mortality in the HIV infected. Southern Africa is
a kaleidoscope of developing and developed worlds where
some, but not all, access ARV medication and clinical support.
The fact that an inexpensive antimicrobial can provide survival
advantage must be taken seriously and this benefit should be
offered to patients whose CD4 count exceeds 200/µl and who
are not on ARVs. However, thorough research into the
appropriateness of such a course of action will be required –
who to give it to, when to stop, and whether benefit is
maintained in the context of the antiretroviral rollout in
southern Africa. Invasive bacterial disease is sufficiently
important in the southern African context to warrant review
in relation to CD4 cell count in much the same decisive way
the Cote d’Ivoire investigators have done (see Fig. 1). Answers
would inform the issues of whether local patients need to be
on CTX when this CD4 count is above 200 cells/µl. Would CTX
prophylaxis benefit those on ART? This question requires an
answer, which will involve clinical research and evidence-
based data. At this time the question in relation to southern
Africa remains unanswered. 
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